Diurnal Group (LON:DNL) Releases Earnings Results, Beats Estimates By $2.40 EPS

Diurnal Group (LON:DNL) announced its quarterly earnings data on Tuesday. The company reported GBX (4.30) (($0.06)) earnings per share for the quarter, beating analysts’ consensus estimates of GBX (6.70) (($0.09)) by GBX 2.40 ($0.03), Digital Look Earnings reports.

Shares of DNL stock traded up GBX 2 ($0.03) during mid-day trading on Tuesday, reaching GBX 56.50 ($0.74). The stock had a trading volume of 224,021 shares, compared to its average volume of 246,254. The business’s fifty day moving average is GBX 51.56 and its 200-day moving average is GBX 36.61. The company has a current ratio of 4.46, a quick ratio of 3.80 and a debt-to-equity ratio of 0.77. Diurnal Group has a 1-year low of GBX 19 ($0.25) and a 1-year high of GBX 69 ($0.90). The firm has a market cap of $68.94 million and a price-to-earnings ratio of -5.23.

In related news, insider Richard Bungay sold 41,873 shares of the firm’s stock in a transaction that occurred on Wednesday, July 15th. The shares were sold at an average price of GBX 30 ($0.39), for a total value of £12,561.90 ($16,414.35).

Diurnal Group Company Profile

Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients, as well as adrenal insufficiency.

See Also: How is inflation measured?

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.